首页> 美国卫生研究院文献>BMC Cancer >A polymorphism at the 3-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

【2h】

A polymorphism at the 3-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

机译：芳香酶基因3-UTR区的多态性定义了绝经后乳腺癌患者对新辅助来曲唑反应不良的亚组

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundAromatase (CYP19A1) regulates estrogen biosynthesis. Polymorphisms in CYP19A1 have been related to the pathogenesis of breast cancer (BC). Inhibition of aromatase with letrozole constitutes the best option for treating estrogen-dependent BC in postmenopausal women. We evaluate a series of polymorphisms of CYP19A1 and their effect on response to neoadjuvant letrozole in early BC.

机译：背景芳香酶（CYP19A1）调节雌激素的生物合成。 CYP19A1基因的多态性与乳腺癌的发病机制有关。来曲唑抑制芳香化酶是治疗绝经后妇女雌激素依赖性BC的最佳选择。我们评估了CYP19A1的一系列多态性及其在BC早期对新辅助来曲唑反应的影响。

著录项

期刊名称 BMC Cancer
作者
Zaida Garcia-Casado; Angel Guerrero-Zotano; Antonio Llombart-Cussac; Ana Calatrava; Antonio Fernandez-Serra; Amparo Ruiz-Simon; Joaquin Gavila; Miguel A Climent; Sergio Almenar; Jose Cervera-Deval; Josefina Campos; Carlos Vazquez Albaladejo; Antonio Llombart-Bosch; Vicente Guillem; Jose A Lopez-Guerrero;
展开▼
作者单位

展开▼
年(卷),期 2010(10),-1
年度 2010
页码 36
总页数 11
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 三阴性乳腺癌患者因新辅助或辅助化疗引起的早发性心脏事件与其基因组DNA中某些新的自噬相关单核苷酸多态性的相关性研究:一项真实世界研究 [J] . Binliang Liu, Yuhui Zhang, Binghe Xu, 癌症（英文版） . 2019,第007期
2. A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole [J] . Zaida Garcia-Casado, Angel Guerrero-Zotano, Antonio Llombart-Cussac, BMC Cancer . 2010,第1期

机译：芳香酶基因3'-UTR区域的多态性定义了绝经后乳腺癌患者对新辅助来曲唑反应不良的亚组
3. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. [J] . Wang L, Ellsworth KA, Moon Cancer research: The official organ of the American Association for Cancer Research, Inc . 2010,第1期

机译：芳香酶基因CYP19中的功能性遗传多态性改变了乳腺癌患者对使用芳香酶抑制剂进行新辅助治疗的反应。
4. 2044 POSTER Phase II trial with letrozole (2.5 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer [J] . A.Llombart Cussac, A.Galán, C.Fuster, European Journal of Cancer Supplements . 2007,第4期

机译：2044年POSTER II期临床试验，使用来曲唑（2.5 mg）对绝经后患有ER / PgR [+]可手术的乳腺癌患者具有最大反应作为新辅助内分泌治疗
5. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019

机译：乳腺MRI辐射射清，用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
6. The Genetics of Aromatase Inhibitor-related Phenotypes in Postmenopausal Women with ER+ Breast Cancer [D] . Dudenkov, Tanda Tosia Murray. 2017

机译：ER +乳腺癌绝经后妇女芳香酶抑制剂相关表型的遗传
7. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors [O] . Liewei Wang, Katarzyna A. Ellsworth, Irene Moon, -1

机译：芳香酶基因CYP19中的功能遗传多态性改变乳腺癌患者与芳香酶抑制剂Neoadjuvant治疗的反应
8. A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole [O] . Zaida Garcia-Casado, Angel Guerrero-Zotano, Antonio Llombart-Cussac, 2010

机译：芳香酶基因3'-UTR区域的多态性定义了绝经后乳腺癌患者对新辅助来曲唑反应不良的亚组

A polymorphism at the 3-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅